{'fraction_non_alphanumeric': 0.041916167664670656, 'fraction_numerical': 0.022754491017964073, 'mean_word_length': 5.741935483870968, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
On the central effects of the GABA agonist fengabine: Psychometric and pharmaco‐EEG studies utilizing imaging methods

In a double‐blind, placebo‐controlled study the pharmacokinetic, encephalotropic, and psychotropic properties of fengabine (FEN)‐a novel GABA receptor agonist–were studied in 15 normal subjects utilizing gas chromatography, quantitative pharmaco‐EEG, and topographical analysis methods as well as psychomeric and psychophysiological techniques. The subjects received randomized and, in weekly intervals, single oral doses of placebo; 200, 400, and 800 mg FEN: as well as 75 mg imipramine (IMI) as reference compound. Blood sampling, EEG recordings, and evaluation of pulse, blood pressure, and side effects were carried out at 0, 1, 2, 4, 6, and 8 hr, with psychometric tests at the same times except the first hour.